Guy P Nohra
CIK 1198330 · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
RENO, NV 89511
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TELA | Director | 23,600 | $0.98 | $23.2K | $0 | 1 | 2026-06-11 |
| BVS | Director | 148,892 | $14.72 | $2.19M | -$75.7K | 13 | 2026-06-04 |
| Allakos Inc. (ALLK) Delisted | 10%+ Owner | 6,467,510 | $0.33 | $2.13M | -$3.46M | 2 | 2021-03-08 |
| ZS Pharma, Inc. (ZSPH) Delisted | Director | — | — | — | $0 | 2 | 2015-06-25 |
| LIFE | 10%+ Owner | 120,411 | $42.30 | $5.09M | $0 | 1 | 2015-05-14 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 432,837 | — | — | -$5.55M | 1 | 2014-11-25 |
| TREVENA INC (TRVN) Delisted | 10%+ Owner | 1,548 | $0.01 | $17 | $16.53M | 1 | 2014-02-07 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 200,000 | $15.25 | $3.05M | $4.40M | 1 | 2013-11-01 |
| TALPHERA, INC. (ACRX) Delisted | Director | 180,773 | $0.86 | $155.5K | $20.78M | 6 | 2013-09-23 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | 10%+ Owner | 2,052,189 | $3.18 | $6.53M | $13.20M | 1 | 2013-07-01 |
| COTHERIX INC (CTRX) Delisted | 0 | — | — | $0 | 1 | 2007-01-09 |
Recent Filings · Page 2 of 5
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-22 | BVS | Grant (A) | — | $0 | EDGAR |
| 2022-04-05 | BVS | Exer (M) | +2,700 | $0 | EDGAR |
| 2022-02-15 | BVS | Exer (M) | +9,000 | $0 | EDGAR |
| 2021-04-05 | BVS | Grant (A) | — | $0 | EDGAR |
| 2021-03-08 | Allakos Inc. (ALLK) Delisted | Sell (S) | −25,768 | -$2.88M | EDGAR |
| 2021-02-16 | BVS | Grant (A) | — | $0 | EDGAR |
| 2020-06-19 | Allakos Inc. (ALLK) Delisted | Sell (S) | −7,692 | -$581.7K | EDGAR |
| 2015-12-21 | — | Disp (D) | −1,000 | -$90.0K | |
| 2015-06-25 | ZS Pharma, Inc. (ZSPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-14 | LIFE | Conv (C) | +8,890,320 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.